Rapamycin inhibits a protein complex called mTOR (mechanistic target of rapamycin), which regulates cell growth, metabolism, and autophagy. When mTOR is constantly active — driven by excess calories and protein — cells grow rapidly but skip essential maintenance like clearing damaged proteins and recycling old organelles.
By periodically suppressing mTOR, rapamycin triggers autophagy — your cells' self-cleaning mechanism. This clears out cellular debris, reduces inflammation, and mimics many of the benefits of caloric restriction without the hunger.
Rapamycin has extended lifespan in yeast, worms, flies, and mice. The most significant study, from the National Institute on Aging, showed a 9-14% lifespan increase in mice even when treatment started late in life. No other drug has shown such consistent results across species.
In humans, a landmark 2014 study by Novartis showed that low-dose rapamycin analogue everolimus actually improved immune function in elderly patients — the opposite of what you'd expect from an immunosuppressant. This flipped the narrative and sparked a wave of longevity research.
Several longevity clinics now prescribe low-dose rapamycin (typically 3-6mg once weekly) off-label for anti-ageing. This intermittent dosing appears to provide the autophagy benefits while minimising immune suppression side effects.
The PEARL trial and other studies are currently testing rapamycin's effects on ageing biomarkers in healthy adults. Until results are in, most longevity researchers recommend focusing on proven lifestyle interventions — exercise, sleep, and nutrition — while monitoring the science closely.
Anyone interested in evidence-based longevity strategies, health optimisation, and understanding the latest research on ageing and healthspan.
You are pregnant, breastfeeding, taking prescription medications, or have a pre-existing medical condition. This content is educational and does not replace professional medical advice.
Join thousands getting science-backed health tips every week.